미국의 유방암 검진 및 진단 시장 규모는 2024년 15억 5,660만 달러에 달했습니다.
이 시장은 예측 기간인 2024-2030년 동안 7.05%의 CAGR로 성장하여 2030년 말까지 23억 4,220만 달러에 달할 것으로 예상됩니다. 미국 유방암 검진 및 진단 시장은 첨단 기술의 도입에 힘입어 두 자릿수 성장세를 이어가고 있습니다. 디지털 맘모그래피로의 전환이 빠르게 진행되고 있으며, 2021년 현재 미국 내 유방암 검사의 약 90%를 디지털 시스템이 차지할 것으로 예상됩니다. 이러한 전환은 특히 젊은 여성과 유방 조직이 조밀한 여성에게 디지털 유방촬영술이 더 민감하다는 연구 결과에 의해 뒷받침되고 있습니다. 또한, 디지털 유방 토모삽입술(DBT)이 기존 2D 유방촬영술보다 더 많은 암을 발견하고 위양성률이 낮다는 연구 결과가 나오면서 디지털 유방촬영술이 더욱 보편화되고 있습니다. 예를 들어, 2021년 9월에 발표된 'Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women'(고령 여성에서 디지털 유방 토모신세션과 유방촬영술의 비교 효과)라는 제목의 연구는 비교 효과)라는 제목의 연구에서는 고령 여성에서 DBT가 2D 유방촬영술에 비해 검진 유방촬영술 1,000장당 2.1장의 암을 더 많이 발견하는 것으로 밝혀졌습니다. 또한, 미국 내 유방암 발병률의 증가와 전문 진단 센터의 증가는 미국 유방암 검진 및 진단 시장의 성장을 더욱 촉진하고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 예측 기간 | 2024-2030년 |
| 2024년 평가 | 15억 5,660만 달러 |
| 2030년 예측 | 23억 4,220만 달러 |
| CAGR | 7.05% |
미국의 유방암 검진 및 진단 시장은 유방 영상 기술의 발전으로 인해 크게 성장하고 있습니다. 중요한 기술 혁신 중 하나는 3D 유방 촬영, 즉 디지털 유방 토모신세시스(Digital Breast Tomosynthesis)입니다. 이는 기존의 2D 유방 촬영술을 크게 개선한 것으로, 2D 영상과 달리 유방 토모신세시스는 서로 다른 각도에서 여러 장의 이미지를 촬영하여 방사선과 의사가 정밀하게 검사할 수 있는 유방의 상세한 레이어 뷰를 생성합니다. 레이어를 생성합니다. 예일대 의대 연구진이 13년간 272,000건 이상의 유방암 검진을 분석한 종합적인 연구에 따르면, 3D 맘모그래피가 2D 맘모그래피보다 유방암을 더 자주, 더 조기에 발견하는 것으로 나타났습니다. 특히, 2차원 유방촬영술의 44%에 비해 3차원 유방촬영술은 33%의 암이 진행된 단계에서 발견되어 조기 발견율이 크게 향상되었습니다. 마찬가지로, 광음향 초음파(광음향 이미징이라고도 함)는 레이저 유도 영상과 기존 초음파 기술을 결합한 혁신적인 진단 도구입니다. 이 방법은 유방암의 검출 및 진단, 특히 양성 병변과 악성 병변의 감별을 강화하는 데 큰 잠재력을 보여주었습니다.
Hologic, GE Healthcare, Siemens Healthineers AG 등 주요 기업들이 주도하는 미국 유방암 검진 및 진단 시장은 3D 맘모그래피, 광음향 초음파 등 첨단 기술을 활용하여 조기 발견을 강화하고 양성 병변과 악성 병변의 감별 정확도를 향상시키는 다양한 진단 솔루션을 제공하고 있습니다. 조기 발견을 강화하고 양성 병변과 악성 병변의 감별 정확도를 향상시키는 다양한 진단 솔루션을 제공하고 있습니다.
미국의 유방암 검진 및 진단 시장에 대해 조사했으며, 시장 개요, 제품별, 최종사용자별, 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.
An Introduction to U.S. Breast Cancer Screening and Diagnostic
The U.S. breast cancer screening and diagnostic market was valued at $1,556.6 million in 2024 and is anticipated to reach $2,342.2 million by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-2030. The U.S. breast cancer screening and diagnostic market has been witnessing impressive double-digit growth, largely driven by the introduction of advanced technologies. The shift to digital mammography has been rapid, with digital systems now accounting for approximately 90% of all mammography procedures in the U.S. as of 2021.This transition has been supported by research showing that digital mammography has greater sensitivity, especially for younger women and those with dense breast tissue. Additionally, digital breast tomosynthesis (DBT) has become more common, as studies indicate it detects more cancers than traditional 2D mammography while also lowering false positive rates. For example, a study published in September 2021 titled 'Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women' found that DBT identified 2.1 more cancers per 1,000 screening mammograms compared to 2D mammography among older women. Moreover, the rising incidence of breast cancer and the increasing number of specialized diagnostic centers in the U.S. have been further propelling U.S. breast cancer screening and diagnostic market growth.
Market Introduction
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2024 - 2030 |
| 2024 Evaluation | $1,556.6 Million |
| 2030 Forecast | $2,342.2 Million |
| CAGR | 7.05% |
The U.S. breast cancer screening and diagnostic market has been experiencing notable growth, driven by advancements in breast imaging technologies. One key innovation is 3-D mammography, or digital breast tomosynthesis, which represents a significant improvement over traditional 2-D mammography. Unlike 2-D images, breast tomosynthesis captures multiple images from different angles to create a detailed, layered view of the breast that radiologists can closely examine. A comprehensive study by researchers at Yale School of Medicine, analyzing over 272,000 breast cancer screenings over 13 years, found that 3-D mammograms identified breast cancer more frequently and at earlier stages than 2-D mammograms. Specifically, the study indicated that 3-D mammography detected 33% of cancers at advanced stages, compared to 44% for 2-D mammography, highlighting a marked improvement in early detection. Similarly, optoacoustic ultrasound, also known as photoacoustic imaging, is an innovative diagnostic tool that combines laser-induced imaging with traditional ultrasound technology. This method has shown significant promise in enhancing the detection and diagnosis of breast cancer, particularly in differentiating between benign and malignant lesions.
Industrial Impact
The U.S. breast cancer screening and diagnostic market, driven by leading companies such as Hologic, GE Healthcare, and Siemens Healthineers AG, has transformed the landscape of breast cancer detection. By leveraging advanced technologies such as 3-D mammography, and optoacoustic ultrasound, these companies provide a diverse range of diagnostic solutions that enhance early detection and improve accuracy in distinguishing between benign and malignant lesions.
The innovations in the U.S. breast cancer screening market have a significant impact that goes beyond just diagnosing individual cases. Improved screening methods, such as digital breast tomosynthesis (DBT) and advanced MRI, provide important data that inform clinical trials and drug development. This data helps create more effective treatment strategies tailored to the unique characteristics of each patient, which is especially vital in breast cancer, where identifying specific biomarkers can lead to targeted therapies that enhance patient outcomes.
Additionally, incorporating these advanced screening technologies into public health initiatives raises awareness and encourages more people to participate in screening programs. This increase in participation leads to higher rates of early detection and timely intervention, improving individual health and strengthening community health systems by reducing the number of late-stage diagnoses.
As these technologies continue to evolve and regulatory support grows, the influence of the breast cancer screening and diagnostic market in the U.S. becomes even more pronounced. By advancing precision medicine and providing deeper insights into breast cancer, U.S. breast cancer screening and diagnostic market plays a crucial role in transforming healthcare practices and improving patient outcomes across the country.
Market Segmentation of the U.S. breast cancer screening and diagnostic market:
Segmentation 1: by Technology
Digital Breast Tomosynthesis Segment to Dominate the U.S. Breast Cancer Screening and Diagnostic, Image-Based Market (by Technology)
Based on product, the U.S. breast cancer screening and diagnostic, image-based market was led by the digital breast tomosynthesis segment, which held a 49.93% share in 2023. The rising adoption of digital breast tomosynthesis (DBT) reflects a strong demand for advanced breast cancer screening technologies. DBT is particularly effective in improving detection rates for women with dense breast tissue, making it a vital tool for early diagnosis. This technology helps reduce false-positive results, leading to better patient experiences and outcomes. The growing recognition of DBT's benefits, supported by clinical guidelines and increased patient awareness, drives its integration into standard screening practices, ultimately advancing breast cancer detection and personalized healthcare solutions which in result propelling the growth of U.S. breast cancer screening and diagnostic market.
Recent Developments in the U.S. Breast Cancer Screening and Diagnostic Market
Demand - Drivers, Challenges, and Opportunities in the U.S. breast cancer screening and diagnostic market
Market Drivers in the U.S. breast cancer screening and diagnostic market:
Growing Incidence of Breast Cancer: The increasing incidence of breast cancer in the U.S. has been a significant factor driving the growth of the breast cancer screening and diagnostic market. According to statistics published by the American Cancer Society in January 2024, there were over 300,000 new cases of breast cancer reported, alongside a continuing prevalence of 3.5 million cases. This trend heightens the demand for early detection technologies, prompting healthcare facilities to invest more in advanced diagnostic tools such as mammography, MRI, and ultrasound. Also, as breast cancer rates rise, the need for early and accurate detection becomes critical, contributing to substantial growth in the U.S. breast cancer screening and diagnostic market. Healthcare providers are thus motivated to enhance their diagnostic capabilities, ensuring better patient outcomes through timely and precise detection.
Market Challenges in the U.S. breast cancer screening and diagnostic market:
Shortage of Imaging Expertise Leading to Underutilization of Breast Cancer Imaging Solutions: Imaging plays a crucial role in ensuring quality cancer care, but it faces significant challenges in both developing and developed countries. Projections from the Association of American Medical Colleges (AAMC) indicate that the U.S. may encounter a physician shortage of between 37,800 and 124,000 by 2034, with radiology alone expected to see a deficit of 10,300 to 35,600 physicians. The AAMC also identifies issues such as physician burnout and an aging workforce as major factors contributing to these shortages. Additionally, research published in July 2023 by the American College of Radiology highlights the effects of these workforce challenges, specifically on radiology. For example, Montana reported the highest attrition rate, with 25.4% of radiologists, i.e., 16 out of 63, leaving the profession. This situation underscores the critical shortage and high turnover rates in radiology, reflecting broader national concerns about physician shortages and the urgent need for effective strategies to address these workforce issues.
Market Opportunities in the U.S. breast cancer screening and diagnostic market:
Utilization of Multi-Modality Imaging for Breast Cancer Screening: The integration of multi-modality imaging in breast cancer screening and diagnosis marks a significant advancement in the field. This approach enhances diagnostic accuracy, aids in precise surgical planning, and facilitates personalized patient care, ultimately leading to better outcomes for those with breast cancer. As technology continues to advance, the role of multi-modality imaging in managing breast cancer is expected to grow, further improving the quality and effectiveness of care. Additionally, the development and incorporation of multimodal diagnostic imaging systems have been driving major improvements in breast cancer screening and diagnosis. These systems combine various imaging techniques, such as mammography, ultrasound, and tomosynthesis, into a single platform, offering a comprehensive evaluation of breast tissue. This holistic approach boosts diagnostic accuracy, especially in challenging cases involving dense breast tissue, and enhances early detection rates.
How can U.S. breast cancer screening and diagnostic market report add value to an organization?
Product/Innovation Strategy: The U.S. breast cancer screening and diagnostic market has been extensively segmented based on technology. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The U.S. breast cancer screening and diagnostic market has numerous established players with significant product portfolios. Key players in the breast cancer screening and diagnostic market analyzed and profiled in the study involve established players offering products for screening and diagnosis of breast cancer.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research in the U.S. breast cancer screening and diagnostic market:
The primary sources involve industry experts in U.S. breast cancer screening and diagnostic, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research in the U.S. breast cancer screening and diagnostic market
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.
Some prominent names established in U.S. breast cancer screening and diagnostic market are: